TABLE I.
Agent | No. of animals (bilateral) | Route | T/C (%) | T–C (days) | Log10 kill
|
Activity score | |
---|---|---|---|---|---|---|---|
Gross | Net | ||||||
Control | 7 | N/A | 100 | 0 | 0.0 | 0.0 | N/A |
B-DIM | 7 | PO | 88 | 2 | 0.37 | N/A | − |
Erlotinib | 7 | IP | 89 | 3 | 0.55 | N/A | − |
Gemcitabine | 7 | IV | 79 | 4 | 0.74 | N/A | + |
B-DIM + erlotinib | 7 | PO + IP | 74 | 7 | 1.3 | N/A | ++ |
B-DIM + gemcitabine | 7 | PO + IV | 76 | 9 | 1.7 | N/A | ++ |
Erlotinib + gemcitabine | 7 | IP + IV | 59 | 14 | 2.6 | 0.37 | +++ |
B-DIM + erl + gem | 7 | PO + IP + IV | 47 | 22 | 4.1 | 1.86 | ++++ |
Doubling time was estimated at 1.62 days.
The drugs were administered for 12 consecutive days.